keyword
MENU ▼
Read by QxMD icon Read
search

age lung cancer gene

keyword
https://www.readbyqxmd.com/read/27908619/correlation-of-dna-repair-gene-polymorphisms-with-clinical-outcome-in-patients-with-locally-advanced-non-small-cell-lung-cancer-receiving-induction-chemotherapy-followed-by-surgery
#1
Mariacarmela Santarpia, Jose Luis Ramirez, Itziar de Aguirre, Pilar Garrido, Maria Pérez Cano, Cristina Queralt, Jose Luis Gonzalez-Larriba, Amelia Insa, Mariano Provencio, Dolores Isla, Carlos Camps, Remei Blanco, Teresa Moran, Rafael Rosell
OBJECTIVE: The aim of this study was to evaluate whether xeroderma pigmentosum group D (XPD) and ribonucleotide reductase subunit M1 (RRM1) polymorphisms influenced clinical outcome in patients with stage IIIA-B non-small-cell lung cancer (NSCLC) treated with neoadjuvant gemcitabine/cisplatin/docetaxel followed by surgery. MATERIALS AND METHODS: A total of 109 patients with stage IIIA and IIIB NSCLC were prospectively genotyped to examine a potential association between XPD 312 (aspartic acid [Asp]/asparagine [Asn]), XPD 751 (lysine [Lys]/glutamine [Gln]), and RRM1 (-37 C/A) polymorphisms with response and survival...
November 9, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27902695/text-mining-genotype-phenotype-relationships-from-biomedical-literature-for-database-curation-and-precision-medicine
#2
Ayush Singhal, Michael Simmons, Zhiyong Lu
The practice of precision medicine will ultimately require databases of genes and mutations for healthcare providers to reference in order to understand the clinical implications of each patient's genetic makeup. Although the highest quality databases require manual curation, text mining tools can facilitate the curation process, increasing accuracy, coverage, and productivity. However, to date there are no available text mining tools that offer high-accuracy performance for extracting such triplets from biomedical literature...
November 2016: PLoS Computational Biology
https://www.readbyqxmd.com/read/27902597/whole-exome-sequencing-of-independent-lung-adenocarcinoma-lung-squamous-cell-carcinoma-and-malignant-peritoneal-mesothelioma-a-case-report
#3
Irene Vanni, Simona Coco, Silvia Bonfiglio, Davide Cittaro, Carlo Genova, Federica Biello, Marco Mora, Valeria Rossella, Maria Giovanna Dal Bello, Anna Truini, Barbara Banelli, Dejan Lazarevic, Angela Alama, Erika Rijavec, Giulia Barletta, Francesco Grossi
The presence of multiple primary tumors (MPT) in a single patient has been identified with an increasing frequency. A critical issue is to establish if the second tumor represents an independent primary cancer or a metastasis. Therefore, the assessment of MPT clonal origin might help understand the disease behavior and improve the management/prognosis of the patient.Herein, we report a 73-year-old male smoker who developed 2 primary lung cancers (adenocarcinoma and squamous cell carcinoma) and a malignant peritoneal mesothelioma (PM)...
November 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27900359/homozygous-inactivation-of-chek2-is-linked-to-a-familial-case-of-multiple-primary-lung-cancer-with-accompanying-cancers-in-other-organs
#4
Yoji Kukita, Jiro Okami, Noriko Yoneda-Kato, Ikuko Nakamae, Takeshi Kawabata, Masahiko Higashiyama, Junya Kato, Ken Kodama, Kikuya Kato
In clinical practice, there are a number of cancer patients with clear family histories, but the patients lack mutations in known familial cancer syndrome genes. Recent advances in genomic technologies have enhanced the possibility of identifying causative genes in such cases. Two siblings, an elder sister and a younger brother, were found to have multiple primary lung cancers at the age of 60. The former subsequently developed breast cancer and had a history of uterine myoma. The latter had initially developed prostate cancer at the age of 59 and had a history of colon cancer...
November 2016: Cold Spring Harbor Molecular Case Studies
https://www.readbyqxmd.com/read/27892978/estimating-survival-in-patients-with-lung-cancer-and-brain-metastases-an-update-of-the-graded-prognostic-assessment-for-lung-cancer-using-molecular-markers-lung-molgpa
#5
Paul W Sperduto, T Jonathan Yang, Kathryn Beal, Hubert Pan, Paul D Brown, Ananta Bangdiwala, Ryan Shanley, Norman Yeh, Laurie E Gaspar, Steve Braunstein, Penny Sneed, John Boyle, John P Kirkpatrick, Kimberley S Mak, Helen A Shih, Alex Engelman, David Roberge, Nils D Arvold, Brian Alexander, Mark M Awad, Joseph Contessa, Veronica Chiang, John Hardie, Daniel Ma, Emil Lou, William Sperduto, Minesh P Mehta
Importance: Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide. As systemic therapies improve, patients with lung cancer live longer and thus are at increased risk for brain metastases. Understanding how prognosis varies across this heterogeneous patient population is essential to individualize care and design future clinical trials. Objective: To update the current Diagnosis-Specific Graded Prognostic Assessment (DS-GPA) for patients with non-small-cell lung cancer (NSCLC) and brain metastases...
November 17, 2016: JAMA Oncology
https://www.readbyqxmd.com/read/27885542/a-consensus-statement-on-the-gender-perspective-in-lung-cancer
#6
REVIEW
D Isla, M Majem, N Viñolas, A Artal, A Blasco, E Felip, P Garrido, J Remón, M Baquedano, J M Borrás, M Die Trill, R García-Campelo, O Juan, C León, P Lianes, F López-Ríos, L Molins, M Á Planchuelo, M Cobo, L Paz-Ares, J M Trigo, J de Castro
Lung cancer is the most common cancer globally and has the highest mortality. Although this disease is not associated with a particular gender, its incidence is rising among women, who are diagnosed at an increasingly younger age compared with men. One of the main reasons for this rise is women taking up smoking. However, many non-smoking women also develop this disease. Other risk factors implicated in the differential development of lung cancer in women are genetic predisposition, tumour histology and molecular profile...
November 24, 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27883280/phase-i-study-of-irinotecan-for-previously-treated-lung-cancer-patients-with-the-ugt1a1-28-or-6-polymorphism-results-of-the-lung-oncology-group-in-kyushu-logik1004a
#7
Minoru Fukuda, Midori Shimada, Takeshi Kitazaki, Seiji Nagashima, Kohji Hashiguchi, Noriyuki Ebi, Koichi Takayama, Yoichi Nakanishi, Hiroshi Semba, Taishi Harada, Takashi Seto, Isamu Okamoto, Yukito Ichinose, Kenji Sugio
BACKGROUND: Various polymorphisms have been detected in the UDP-glucuronosyltransferase 1A ( UGT1A ) gene, and UGT1A1 *28 and UGT1A1 *6 have important effects on the pharmacokinetics of irinotecan and the risk of severe toxicities during irinotecan therapy. This study was conducted to determine the maximum tolerated dose (MTD) of irinotecan chemotherapy according to the UGT1A1 genotype in previously treated lung cancer patients with the UGT1A1 *28 or UGT1A1 *6 polymorphism. METHODS: The eligibility criteria were as follows: lung cancer patients that had previously been treated with anticancer agents other than irinotecan, possessed the UGT1A1 *28 or UGT1A1 *6 polymorphism (group A included *28/*28, *6/*6, and *28/*6, and group B included *28 /- and *6 /-), were aged ≤75 years old, had a performance score of 0-1, and exhibited adequate bone marrow function...
November 24, 2016: Thoracic Cancer
https://www.readbyqxmd.com/read/27877056/a-retrospective-analysis-of-the-clinicopathological-and-molecular-characteristics-of-pulmonary-blastoma
#8
Yuan-Yuan Zhao, Lin Liu, Ting Zhou, Ning-Ning Zhou, Yun-Peng Yang, Xue Hou, Yong Li, Hong-Yun Zhao, Yan Huang, Li Zhang
PURPOSE: The aim of this study was to analyze and summarize the clinicopathological and molecular characteristics of classic biphasic pulmonary blastoma (PB) to improve its diagnosis and treatment. PATIENTS AND METHODS: A retrospective analysis was performed in patients who were diagnosed with PB at Sun Yat-Sen University Cancer Center from March 1995 to March 2015. Genomic DNA was profiled using a capture-based targeted sequencing panel. RESULTS: Sixteen patients with an average age of 40 years were included in this study...
2016: OncoTargets and Therapy
https://www.readbyqxmd.com/read/27869174/developmental-reprogramming-in-mesenchymal-stromal-cells-of-human-subjects-with-idiopathic-pulmonary-fibrosis
#9
Diptiman Chanda, Ashish Kurundkar, Sunad Rangarajan, Morgan Locy, Karen Bernard, Nirmal S Sharma, Naomi J Logsdon, Hui Liu, David K Crossman, Jeffrey C Horowitz, Stijn De Langhe, Victor J Thannickal
Cellular plasticity and de-differentiation are hallmarks of tissue/organ regenerative capacity in diverse species. Despite a more restricted capacity for regeneration, humans with age-related chronic diseases, such as cancer and fibrosis, show evidence of a recapitulation of developmental gene programs. We have previously identified a resident population of mesenchymal stromal cells (MSCs) in the terminal airways-alveoli by bronchoalveolar lavage (BAL) of human adult lungs. In this study, we characterized MSCs from BAL of patients with stable and progressive idiopathic pulmonary fibrosis (IPF), defined as <5% and ≥10% decline, respectively, in forced vital capacity over the preceding 6-month period...
November 21, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27866339/recurrent-tp53-missense-mutation-in-cancer-patients-of-arab-descent
#10
Aviad Zick, Luna Kadouri, Sherri Cohen, Michael Frohlinger, Tamar Hamburger, Naama Zvi, Morasha Plaser, Eilat Avital, Shani Breuier, Firase Elian, Azzam Salah, Yael Goldberg, Tamar Peretz
Hereditary cancer comprises more than 10% of all breast cancer cases. Identification of germinal mutations enables the initiation of a preventive program that can include early detection or preventive treatment and may also have a major impact on cancer therapy. Several recurrent mutations were identified in the BRCA1/2 genes in Jewish populations however, in other ethnic groups in Israel, no recurrent mutations were identified to date. Our group established panel sequencing in cancer patients to identify recurrent, founder, and new mutations in the heterogeneous and diverse populations in Israel, We evaluated five breast cancer patients of Arab descent diagnosed with cancer before the age of 50 years and identified the previously described TP53 mutation, c...
November 19, 2016: Familial Cancer
https://www.readbyqxmd.com/read/27859136/kras-driven-expression-signature-has-prognostic-power-superior-to-mutation-status-in-non-small-cell-lung-cancer
#11
Ádám Nagy, Lőrinc Sándor Pongor, András Szabó, Mariacarmela Santarpia, Balázs Győrffy
KRAS is the most frequently mutated oncogene in non-small cell lung cancer (NSCLC). However, the prognostic role of KRAS mutation status in NSCLC still remains controversial. We hypothesize that the expression changes of genes affected by KRAS mutation status will have the most prominent effect and could be used as a prognostic signature in lung cancer. We divided NSCLC patients with mutation and RNA-seq data into KRAS mutated and wild type groups. Mann-Whitney test was used to identify genes showing altered expression between these cohorts...
November 8, 2016: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/27836716/activity-and-safety-of-brigatinib-in-alk-rearranged-non-small-cell-lung-cancer-and-other-malignancies-a-single-arm-open-label-phase-1-2-trial
#12
Scott N Gettinger, Lyudmila A Bazhenova, Corey J Langer, Ravi Salgia, Kathryn A Gold, Rafael Rosell, Alice T Shaw, Glen J Weiss, Meera Tugnait, Narayana I Narasimhan, David J Dorer, David Kerstein, Victor M Rivera, Timothy Clackson, Frank G Haluska, David Ross Camidge
BACKGROUND: Anaplastic lymphoma kinase (ALK) gene rearrangements are oncogenic drivers of non-small-cell lung cancer (NSCLC). Brigatinib (AP26113) is an investigational ALK inhibitor with potent preclinical activity against ALK mutants resistant to crizotinib and other ALK inhibitors. We aimed to assess brigatinib in patients with advanced malignancies, particularly ALK-rearranged NSCLC. METHODS: In this ongoing, single-arm, open-label, phase 1/2 trial, we recruited patients from nine academic hospitals or cancer centres in the USA and Spain...
November 7, 2016: Lancet Oncology
https://www.readbyqxmd.com/read/27827952/cell-free-rna-content-in-peripheral-blood-as-potential-biomarkers-for-detecting-circulating-tumor-cells-in-non-small-cell-lung-carcinoma
#13
Xin-Min Yu, Yi-Chen Wu, Xiang Liu, Xian-Cong Huang, Xiu-Xiu Hou, Jiu-Li Wang, Xiang-Liu Cheng, Wei-Min Mao, Zhi-Qiang Ling
Circulating tumor cells (CTCs) have been implicated in tumor progression and prognosis. Techniques detecting CTCs in the peripheral blood of patients with non-small cell lung carcinoma (NSCLC) may help to identify individuals likely to benefit from early systemic treatment. However, the detection of CTCs with a single marker is challenging, owing to low specificity and sensitivity and due to the heterogeneity and rareness of CTCs. Herein, the probability of cell-free RNA content in the peripheral blood as a potential biomarker for detecting CTCs in cancer patients was investigated...
November 5, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27816393/association-of-pd-1-pd-l1-and-ctla-4-gene-expression-and-clinicopathologic-characteristics-in-patients-with-non-small-cell-lung-cancer
#14
Aránzazu Lafuente-Sanchis, Ángel Zúñiga, Miriam Estors, Néstor J Martínez-Hernández, Antonio Cremades, María Cuenca, José M Galbis
INTRODUCTION: Recent studies show a potential benefit of therapies that target programmed death receptor 1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitory checkpoints in a subgroup of patients with non-small-cell lung cancer (NSCLC), without the clinicopathologic characteristics related to positive responses to these treatments being well determined. The aim of this study was to determine PD-1, PD-L1, and CTLA-4 gene expression at the mRNA level in tumoral tissue from patients with NSCLC and analyze their possible relationship with the clinicopathological characteristics and their potential prognostic role...
October 17, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27815686/cdk4-in-lung-and-head-and-neck-cancers-in-old-age-evaluation-as-a-biomarker
#15
J Banerjee, R Pradhan, A Gupta, R Kumar, V Sahu, A D Upadhyay, P Chaterjee, S Dwivedi, S Dey, A B Dey
BACKGROUND: Cyclin dependent kinases (CDK) are key factors in promoting the initiation and development of tumors. These kinases are important for maintenance of mitochondrial biogenesis and imbalance in their expression in old age may lead to the oxidative stress. Lung cancer (LC), and head and neck squamous cell carcinoma (HNSCC) are two very prominent cancers in older Indians. Both the cancers are showing increasing trend in older population. The present study assessed serum concentration of one of the kinases; CDK4 in older LC and HNSCC patients...
November 4, 2016: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/27814341/association-between-microrna-125a-rs12976445-c-t-polymorphism-and-18f-fluorodeoxyglucose-18fdg-uptake-clinical-and-metabolic-response-in-patients-with-non-small-cell-lung-cancer
#16
Zhina Zang, Wenhua Guan, Diansen Chen, Yan Han, Zhan Shi, Jinjin Zhou
BACKGROUND MicroRNA-125a (miR-125a) has been involved with many diseases, such as hepatocellular carcinoma and inflammation. In this study, we aimed to investigate the molecular mechanism, including the potential regulator and signaling pathways, of vascular endothelial growth factor (VEGF). MATERIAL AND METHODS We divided the participants into 3 groups by rs12976445 genotype and performed chi-square tests to evaluate the differences between CC and CT+TT groups for sex, age, grading, pT category, metastases, and fludeoxyglucose F18 injection (18FDG) metabolism...
November 4, 2016: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/27796337/phenotype-genotype-correlation-in-multiple-primary-lung-cancer-patients-in-china
#17
Yang Yang, Wei Yin, Wenxin He, Chao Jiang, Xiao Zhou, Xiao Song, Junjie Zhu, Ke Fei, Weijun Cao, Gening Jiang
Due to recent advances in high-resolution detection technology, multiple primary lung cancer (MPLC) is becoming an increasingly common diagnosis. However, the genotype-phenotype correlations in MPLC patients have not yet been assessed. In this study, we analyzed the clinical and pathological data for 129 consecutive MPLC patients who received curative surgery at the Tongji University Shanghai Pulmonary Hospital, China. We have screened 129 patients in the present study and found mutations in EGFR, BRAF, ROS1 and KRAS genes, as well as the rearrangement of the EML4-ALK gene in 113 patients...
October 31, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27794412/prediction-of-distant-recurrence-in-resected-stage-i-and-ii-lung-adenocarcinoma
#18
Beatrice Aramini, Christian Casali, Alessandro Stefani, Stefania Bettelli, Susanne Wagner, Zaina Sangale, Elisha Hughes, Jerry S Lanchbury, Antonino Maiorana, Uliano Morandi
OBJECTIVES: Optimal procedures for adjuvant treatment and post-surgical surveillance of resected non-small-cell lung cancer remain under discussion. Pathological features are the main determinant of follow-up therapy but have limited ability to identify patients at risk of recurrence. Increasingly, molecular markers are incorporated into clinical decision-making, including measures of tumor growth. The CCP score is a quantitative, molecular measure of proliferation derived from the RNA expression of 31 cell cycle genes and a component of the molecular prognostic score (mPS)...
November 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27794403/clinicopathologic-characteristics-genetic-variability-and-therapeutic-options-of-ret-rearrangements-patients-in-lung-adenocarcinoma
#19
Zhengbo Song, Xinmin Yu, Yiping Zhang
BACKGROUND: RET fusion gene is identified as a novel oncogene in a subset of non-small cell lung cancer (NSCLC). However, few data are available about the prevalence, clinicopathologic characteristics, genetic variability and therapeutic options in RET-positive lung adenocarcinoma patients. PATIENTS AND METHODS: For 615 patients with lung adenocarcinoma, RET status was detected by reverse transcription-polymerase chain reaction (RT-PCR). Next-generation sequencing (NGS) and FISH were performed in positive cases...
November 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/27793199/epidemiological-study-of-her-2-mutations-among-egfr-wild-type-lung-adenocarcinoma-patients-in-china
#20
Xuefei Li, Chao Zhao, Chunxia Su, Shengxiang Ren, Xiaoxia Chen, Caicun Zhou
BACKGROUND: Human epidermal growth factor receptor (HER)-2 is a driver gene in non-small cell lung cancer (NSCLC). The present study evaluated the mutation rate of HER-2 within the wild-type epidermal growth factor receptor (EGFR) lung adenocarcinoma population in China. METHODS: Formalin-fixed, paraffin-embedded samples from 456 patients with wild-type EGFR lung adenocarcinoma were analyzed for HER-2 mutations by amplification-refractory mutation system (ARMS), and HER-2 protein expression was evaluated by immunohistochemistry...
October 28, 2016: BMC Cancer
keyword
keyword
17667
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"